Last mentioned: Mar 6, 2026
Earnings Calls
Management teams for both companies host conference calls to provide strategic updates and 2026 outlook.
Transcript Release
Full transcripts of the Q4 2025 earnings calls are made available to the public and analysts.
SEC Filings
Both ACFN and CRMD file 8-K reports detailing Q4 and full-year 2025 financial results.
Acorn Energy and CorMedix both reported Q4 2025 financial results on March 5, 2026, marking a critical transition from development to commercial scaling. While Acorn focuses on high-margin IoT recurring revenue, CorMedix is navigating the complex rollout of its lead product, DefenCath, in the dialysis market.
This page surfaces every story mentioning DefenCath across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where DefenCath was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |